(Link:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2}.html) is a drug for the treatment of type 2 diabetes and belongs to the insulin-like peptide-1 receptor agonist (GLP-1 RA). Chemical formula C187H291N45O59, CAS CAS 910463-68-2. It is a white to off-white powder. It is soluble in water and forms a clear to slightly cloudy solution with a solubility in water of about 10 mg/mL, and can also be dissolved in some organic solvents such as alcohols and dimethyl sulfoxide. It is a synthetic similar peptide. In the chemical structure of semaglutide, there is also a cysteine residue, which is connected to other amino acid residues by disulfide bonds. Relatively stable under normal drug storage conditions. It can be stored for a long time under refrigerated conditions (2-8 degrees Celsius). The finished drug of this chemical product has many clinical uses, but the product produced by Shaanxi Chuchan Chemical Co., Ltd. is a primary chemical product and is only used for scientific research.
Semaglutide is an insulin-like peptide-1 receptor agonist (GLP-1 RA), maprinly used in the treatment of type 2 diabetes. In addition to treating diabetes, semaglutide is being investigat for several other potential uses.
1. Diabetes treatment:
Semaglutide is a a li jaġixxi fit-tul GLP-1 receptor agonist that reduces blood sugar levels by mimicking the action of insulin-like peptide-1 (GLP-1}) produced in the body. It jistimula the secretion of insulin, jinibixxi the secretion of glucagon, and slows the emptying of the gastrointestinal tract, thereby reducing the rise in blood sugar after food intake. Il li jaħdem fit-tul natura ta ' semaglutide jippermetti it biex tipprovdi sostnut glycemic kontroll bħala a darba fil-ġimgħa injezzjoni.
2. Piż ġestjoni:
In addition to treating diabetes, semaglutide is also used for weight management. Clinical trials have shown that obese patients treated with semaglutide can achieve significant weight loss comcompared to placebo. Semaglutide works by suppressing appetite and increasing satiety, thereby reducing energy intake. Therefore, it is huwa kkunsidrat as a potential therapeutic tool for obesity.
3. Kardjovaskulari protezzjoni:
Semaglutide has also shown a protective effect on the cardiovascular system. In the cardiovascular safety trial, diabetic patients treated with semaglutide had a significantly lower risk of cardiovascular events (such as heart attack, stroke) compared with placebo. This indics that semaglutide may have the effect of reducing the risk of reducing the risk of cardiovascular disease, li may be related to improving insulina resistance, reducing insulin reżistenza u titjib demm xaħam metaboliżmu.
4. Kroniku kliewi mard trattament:
Recent clinical trials have shown that semaglutide also shows potential in the treatment of chronic kliewi disease. Type 2 diabetic patients treated with semaglutide not only have good blood sugar control, but also have significant improvement in renal function indicators. In addition, semaglutide reduces urinary albumin excretion, an indicator of kliewi marda.
5. Lipidu metaboliżmu diżordni:
Semaglutide ukoll itejjeb lipidi metaboliżmu u jbaxxi demm trigliċeridi u kolesterol livelli. Dan is speċjalment importanti għal dijabetiċi, as huma spiss għandhom anormali lipidi metaboliżmu.
Semaglutide is a drug that belongs to the class of insulin-like peptide-1 receptor agonists (GLP-1 RA). But it is also a chemical product. As a professional chemical company, we have also conducted detailed research on its chemical properties when studying the use of this product. After many tests, we have the following properties:
1. Kimika reazzjoni:
- Idroliżi: Semaglutide jgħaddi minn undergoes a idroliżi reazzjoni in ilma, u tiegħu peptide katina is imkisser f'amin aminku aċidu/residwi by ilma molekuli. din idroliżi reazzjoni jista' jseħħ in vitro jew in vivo.
- Protease Degradation: Semaglutide may be degraded by proteases in vivo. Proteases further cleave the peptide chain into smaller fragments, eventwalment forming amino acid residues.
- Ossidazzjoni: Semaglutide fih multiplu sulfite gruppi (S-S), li jista' be ossidizzat għal disulfide bonds (S-S) taħt ossidattivi kundizzjonijiet.
- Acetylase-catalyzed reaction: The acetate linkage (Ac-O-) in Semaglutide may be hydrolyzed to the corresponding hydroxyl compound by acetate-catalyzed enzymes.
2. Farmakokinetika u in vivo reazzjonijiet:
- Absorption: Semaglutide is amministrat by subcutaneous injection. This route of administration promotes the absorption of the drug and achieves the highest concentration in the blood. After injection, semaglutide is released slowly, provi sostnut azzjoni.
- Distribuzzjoni: In demm ċirkolazzjoni, Semaglutide can bind to plasma proteini. It can also reach target tissues and organs through blood circulation.
- Metabolism: Semaglutide is metabolized by the liver and other tissues mainly through the metabolism of insulinase and other enzymes. These enzymes degrade the peptide chain of semaglutide and convert it into amino acid residues or smaller fragments.
- Eskrezzjoni: Semaglutide is eskreta via il kliewi u feces. Semaglutide li mhux ġie metabolizzat jew assorbit is eskreta mhux mibdul inbidl fl l-awrina.
3. Droga interazzjonijiet:
- Insulin u orali ipogliċemiku drogi: Meta użat konkomitanti ma insulina u orali ipogliċemiku drogi, semaglutide jista' itejjeb l-ipogliċemiku effett ta' dawn drogi. Għalhekk, id-doża of insulina u orali ipogliċemija drogi għandu jkun aġġustat aġġustat qabel użu semaglutide.
- Digestive Enzyme Inhibitors: Digestive enzyme inhibitors (such as orlistat) may affect the absorption of semaglutide. Therefore, it may be necessary to adjust the dose or timing of semaglutide when these drugs are used concomitantly.